CA1046405A - Human sterilization - Google Patents
Human sterilizationInfo
- Publication number
- CA1046405A CA1046405A CA269,084A CA269084A CA1046405A CA 1046405 A CA1046405 A CA 1046405A CA 269084 A CA269084 A CA 269084A CA 1046405 A CA1046405 A CA 1046405A
- Authority
- CA
- Canada
- Prior art keywords
- gel
- composition
- carrier
- accordance
- promoting agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000001954 sterilising effect Effects 0.000 title claims abstract description 11
- 238000004659 sterilization and disinfection Methods 0.000 title claims abstract description 11
- 239000000126 substance Substances 0.000 claims abstract description 47
- 210000003101 oviduct Anatomy 0.000 claims abstract description 40
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 230000001737 promoting effect Effects 0.000 claims abstract description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 36
- 230000008467 tissue growth Effects 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical group [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 claims description 12
- 230000012010 growth Effects 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 10
- 230000036760 body temperature Effects 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 229910001961 silver nitrate Inorganic materials 0.000 claims description 6
- 229960000901 mepacrine Drugs 0.000 claims description 5
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 claims description 5
- 231100000331 toxic Toxicity 0.000 claims description 5
- 230000002588 toxic effect Effects 0.000 claims description 5
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 229920001400 block copolymer Polymers 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 229960005491 sodium morrhuate Drugs 0.000 claims description 3
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- -1 aluminum ion Chemical class 0.000 claims description 2
- GRIXGZQULWMCLU-UHFFFAOYSA-L disodium;7-[[2-carboxylato-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].C12OCC(CSC=3N(N=NN=3)C)=C(C([O-])=O)N2C(=O)C1(OC)NC(=O)C(C([O-])=O)C1=CC=C(O)C=C1 GRIXGZQULWMCLU-UHFFFAOYSA-L 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229920002723 Poly(methyl cyanoacrylate) Polymers 0.000 claims 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims 1
- 150000003378 silver Chemical class 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 31
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 74
- 210000001519 tissue Anatomy 0.000 description 33
- 239000000243 solution Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 239000013043 chemical agent Substances 0.000 description 11
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 239000012530 fluid Substances 0.000 description 7
- 229910021645 metal ion Inorganic materials 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003349 gelling agent Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000001879 gelation Methods 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 229920001992 poloxamer 407 Polymers 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000005243 fluidization Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- SNVFDPHQAOXWJZ-UHFFFAOYSA-N Furcelleran Chemical compound CCOC(=O)C1=C(C)NC(C=2C=CC=CC=2)=C(C(=O)OCC=2C=CC=CC=2)C1C#CC1=CC=CC=C1 SNVFDPHQAOXWJZ-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 208000020983 Scarring Diseases 0.000 description 1
- 239000004115 Sodium Silicate Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002561 chemical irritant Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002344 fibroplastic effect Effects 0.000 description 1
- ISXSFOPKZQZDAO-UHFFFAOYSA-N formaldehyde;sodium Chemical compound [Na].O=C ISXSFOPKZQZDAO-UHFFFAOYSA-N 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 239000003229 sclerosing agent Substances 0.000 description 1
- 208000014745 severe cutaneous adverse reaction Diseases 0.000 description 1
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
- 229910052911 sodium silicate Inorganic materials 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
- A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
Landscapes
- Health & Medical Sciences (AREA)
- Reproductive Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64664976A | 1976-01-05 | 1976-01-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1046405A true CA1046405A (en) | 1979-01-16 |
Family
ID=24593898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA269,084A Expired CA1046405A (en) | 1976-01-05 | 1977-01-04 | Human sterilization |
Country Status (6)
| Country | Link |
|---|---|
| JP (1) | JPS5287238A (enrdf_load_stackoverflow) |
| CA (1) | CA1046405A (enrdf_load_stackoverflow) |
| DE (1) | DE2700190A1 (enrdf_load_stackoverflow) |
| FR (1) | FR2336945A1 (enrdf_load_stackoverflow) |
| GB (1) | GB1554783A (enrdf_load_stackoverflow) |
| NL (1) | NL7614190A (enrdf_load_stackoverflow) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE431821B (sv) | 1979-01-29 | 1984-03-05 | Perstorp Ab | Lagringsstabilt, prostaglandininnehallande medicinskt preparat |
| FR2642306A1 (fr) * | 1989-01-31 | 1990-08-03 | Zipper Jaime | Nouveaux agents pharmacologiques pour la sterilisation feminine par voie intra-uterine et leur emploi therapeutique |
| CA2040460C (en) * | 1990-05-01 | 1997-06-10 | Tacey X. Viegas | Drug delivery with thermoreversible gels |
| US5593683A (en) * | 1990-05-01 | 1997-01-14 | Mdv Technologies, Inc. | Method of making thermoreversible polyoxyalkylene gels |
| RU2568364C1 (ru) * | 2014-06-26 | 2015-11-20 | Государственное Научное Учреждение Научно-исследовательский институт ветеринарии Восточной Сибири Россельхозакадемии | Способ для кастрации самцов сельскохозяйственных животных |
| CN113413490B (zh) * | 2021-05-14 | 2022-05-27 | 哈尔滨医科大学 | 一种超声响应性复合水凝胶及其制备方法和应用 |
-
1976
- 1976-12-20 GB GB5313576A patent/GB1554783A/en not_active Expired
- 1976-12-21 NL NL7614190A patent/NL7614190A/xx not_active Application Discontinuation
- 1976-12-30 JP JP16101276A patent/JPS5287238A/ja active Pending
-
1977
- 1977-01-03 FR FR7700004A patent/FR2336945A1/fr active Granted
- 1977-01-04 DE DE19772700190 patent/DE2700190A1/de not_active Withdrawn
- 1977-01-04 CA CA269,084A patent/CA1046405A/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DE2700190A1 (de) | 1977-07-14 |
| FR2336945A1 (fr) | 1977-07-29 |
| FR2336945B1 (enrdf_load_stackoverflow) | 1981-11-27 |
| NL7614190A (nl) | 1977-07-07 |
| GB1554783A (en) | 1979-10-31 |
| JPS5287238A (en) | 1977-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4185618A (en) | Promotion of fibrous tissue growth in fallopian tubes for female sterilization | |
| US5071644A (en) | Topical drug delivery with thermo-irreversible gels | |
| US5069906A (en) | Intra-vaginal device and method | |
| CA1198643A (en) | Device and method for reversibly occluding a body duct | |
| US5376693A (en) | Thermo-irreversible gel corneal contact lens formed in situ | |
| RU2379025C2 (ru) | Противоинфекционные композиции в виде гидрогеля | |
| US4888168A (en) | Stable ophthalmic preparations containing acetazolamide | |
| US5847023A (en) | Thermal irreversible gel corneal contact lens formed in situ | |
| US4956350A (en) | Wound filling compositions | |
| US20020064514A1 (en) | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels | |
| US4368186A (en) | Methods and compositions for intravaginal contraception | |
| US4707362A (en) | Sustained release composition | |
| US4067961A (en) | Controlled release article | |
| CA1046405A (en) | Human sterilization | |
| PT88220B (pt) | Processo de preparacao de um implante com accao contraceptiva | |
| DE69722805T2 (de) | Methode zur sterilisation männlicher säugetiere | |
| WO2019090239A1 (en) | Radiation sterilized hydrogels, medical devices including radiation sterilized hydrogels and methods of making the same | |
| US5488075A (en) | Contraceptive for use by a male | |
| JP2000506920A (ja) | アルギナートを含む抗菌成分 | |
| CA2367414C (en) | An improved reversible contraceptive for male and female | |
| US8042548B2 (en) | Occlusion of fallopian tubes | |
| JPS5931714A (ja) | 避妊組成物 | |
| JPS6040407B2 (ja) | 薬剤送り出し装置 | |
| US4692143A (en) | Unit package containing ready-to-use vaginal contraceptive | |
| US5609866A (en) | Radiation sterilizable antimicrobial ointment and process to manufacture |